These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11981485)

  • 1. [Polycystic ovaries in 2001: physiology and treatment].
    Chang RJ
    J Gynecol Obstet Biol Reprod (Paris); 2002 Apr; 31(2 Pt 2):1S15-1S9. PubMed ID: 11981485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A practical approach to the diagnosis of polycystic ovary syndrome.
    Chang RJ
    Am J Obstet Gynecol; 2004 Sep; 191(3):713-7. PubMed ID: 15467530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of nonclassic adrenal hyperplasia (NCAH) in hyperandrogenic women.
    Fanta M; Cibula D; Vrbíková J
    Gynecol Endocrinol; 2008 Mar; 24(3):154-7. PubMed ID: 18335331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism.
    Carmina E; Rosato F; Jannì A; Rizzo M; Longo RA
    J Clin Endocrinol Metab; 2006 Jan; 91(1):2-6. PubMed ID: 16263820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations.
    Housman E; Reynolds RV
    J Am Acad Dermatol; 2014 Nov; 71(5):847.e1-847.e10; quiz 857-8. PubMed ID: 25437977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of adolescent polycystic ovary syndrome.
    Hardy TS; Norman RJ
    Steroids; 2013 Aug; 78(8):751-4. PubMed ID: 23624032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of PCOS in adolescence.
    Warren-Ulanch J; Arslanian S
    Best Pract Res Clin Endocrinol Metab; 2006 Jun; 20(2):311-30. PubMed ID: 16772160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dermatology of androgen-related disorders.
    Essah PA; Wickham EP; Nunley JR; Nestler JE
    Clin Dermatol; 2006; 24(4):289-98. PubMed ID: 16828411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth.
    Harwood K; Vuguin P; DiMartino-Nardi J
    Horm Res; 2007; 68(5):209-17. PubMed ID: 17426408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What every physician should know about polycystic ovary syndrome.
    Rosenfield RL
    Dermatol Ther; 2008; 21(5):354-61. PubMed ID: 18844713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified dexamethasone and gonadotropin-releasing hormone agonist (Dx-GnRHa) test in the evaluation of androgen source(s) in hirsute women.
    Bidzińska B; Tworowska U; Demissie M; Milewicz A
    Przegl Lek; 2000; 57(7-8):393-6. PubMed ID: 11109312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
    Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
    Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic Syndrome: Polycystic Ovary Syndrome.
    Mortada R; Williams T
    FP Essent; 2015 Aug; 435():30-42. PubMed ID: 26280343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options of polycystic ovary syndrome in adolescence.
    Zapanti E; Kiapekou E; Loutradis D
    Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():208-13. PubMed ID: 16641862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of functional ovarian hyperandrogenism in women with androgen excess.
    Ehrmann DA; Rosenfield RL; Barnes RB; Brigell DF; Sheikh Z
    N Engl J Med; 1992 Jul; 327(3):157-62. PubMed ID: 1319000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome.
    Amato MC; Galluzzo A; Merlino S; Mattina A; Richiusa P; Criscimanna A; Giordano C
    Eur J Endocrinol; 2006 Dec; 155(6):859-65. PubMed ID: 17132756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sertoli-Leydig cell tumour (arrhenoblastoma) in a patient with polycystic ovary syndrome: clinical, ultrasonographic, hormonal and histopathological evaluation].
    Puzigaća S; Prelević G; Svetenović Z; Djuricić S; Kokan Dj; Radivojević U
    Srp Arh Celok Lek; 2001; 129 Suppl 1():51-5. PubMed ID: 15637992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.